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Abstract Soluble epoxide hydrolase (sEH) is a promising
therapeutic target for the treatment of hypertension, pain,
and inflammation-related diseases. In order to enable the
development of sEH inhibitors (sEHIs), assays are needed
for determination of their potency. Therefore, we developed
a new method utilizing an epoxide of arachidonic acid (14
(15)-EpETrE) as substrate. Incubation samples were direct-
ly injected without purification into an online solid phase
extraction (SPE) liquid chromatography electrospray ioni-
zation tandem mass spectrometry (LC–ESI–MS–MS) setup
allowing a total run time of only 108 s for a full gradient
separation. Analytes were extracted from the matrix within
30 s by turbulent flow chromatography. Subsequently, a full
gradient separation was carried out on a 50X2.1 mm RP-18
column filled with 1.7 μmc o r e –shell particles. The
analytes were detected with high sensitivity by ESI–MS–
MS in SRM mode. The substrate 14(15)-EpETrE eluted at a
stable retention time of 96±1 s and its sEH hydrolysis
product 14,15-DiHETrE at 63±1 s with narrow peak width
(full width at half maximum height: 1.5±0.1 s). The
analytical performance of the method was excellent, with
a limit of detection of 2 fmol on column, a linear range of
over three orders of magnitude, and a negligible carry-over
of 0.1% for 14,15-DiHETrE. The enzyme assay was carried
out in a 96-well plate format, and near perfect sigmoidal
dose–response curves were obtained for 12 concentrations
of each inhibitor in only 22 min, enabling precise
determination of IC50 values. In contrast with other
approaches, this method enables quantitative evaluation of
potent sEHIs with picomolar potencies because only
33 pmol L
−1 sEH were used in the reaction vessel. This
was demonstrated by ranking ten compounds by their
activity; in the fluorescence method all yielded IC50≤
1 nmol L
−1. Comparison of 13 inhibitors with IC50 values
>1 nmol L
−1 showed a good correlation with the fluores-
cence method (linear correlation coefficient 0.9, slope 0.95,
Spearman’s rho 0.9). For individual compounds, however,
up to eightfold differences in potencies between this and the
fluorescence method were obtained. Therefore, enzyme
assays using natural substrate, as described here, are
indispensable for reliable determination of structure–activ-
ity relationships for sEH inhibition.
Keywords Soluble epoxide hydrolase (sEH).Natural
substrate enzyme assay.Enzyme inhibitors turbulent-flow
chromatography.Online-solid phase extraction.Liquid
chromatography.Electrospray mass spectrometry tandem
mass spectrometry
Introduction
Soluble epoxide hydrolase (sEH) inhibitors are a promising
new class of potential drugs for treatment of a variety of
diseases, for example inflammation, hypertension, and pain
[1, 2]. In order to develop new sEH inhibitors (sEHI)
analytical techniques are needed to identify active com-
pounds and quantitatively measure their potencies. Several
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substrates [3], for example cyano(6-methoxynaphthalen-2-
yl)methyl trans-[(3-phenyloxiran-2-yl)methyl] carbonate
(CMNPC) [4, 5] or tritium-labeled trans-diphenylpropene
oxide (t-DPPO)[6]. However, because of the different
recognition of dissimilar substrates by the enzyme, the
measured potencies of sEHIs may differ among these
methods. In order to obtain results predictive for in-vivo
potency inhibition, assays utilizing the natural substrates
are advantageous. Modern mass spectrometry (MS) enables
parallel measurement of many natural enzyme substrates
and products and is, thus, an excellent tool for measurement
of enzyme activity and inhibition [7–11]. For the sEH,
known natural substrates are epoxy fatty acids, which are
metabolized to their corresponding fatty acid diols [12, 13].
Among the epoxy fatty acids, arachidonic acid epoxides
(EpETrEs) are best characterized. These have several
biological effects, for example vasodilatory, anti-
inflammatory, and analgesic activity [1, 2, 14–17].
EpETrEs and their corresponding diols (DiHETrEs) can
be sensitively detected by liquid chromatography electro-
spray (LC–ESI) MS [18, 19]. Consequentially, LC–ESI–
MS has already been used to monitor conversion of 14(15)-
EpETrE to 14,15-DiHETrE [3]. However, no LC–MS-
based approach using natural a substrate has been described
for the rapid determination of the potency of sEHI. For
maximum sEH activity in cell-free in-vitro assays, volatile
salts and stabilizing protein BSA are usually present in high
concentrations [3]. Therefore, direct injection of these
samples on conventional LC columns may lead to an
irreversible absorption of proteins on the stationary phase,
resulting in loss of chromatographic efficiency [20].
Moreover ESI–MS detection is significantly affected by
this matrix, because of signal suppression or enhancement
[21]. Matrix effects can still occur even when most of the
proteins have been precipitated by organic solvent and
removed by centrifugation [22]. Thus, a sample preparation
step is needed before LC–ESI–MS analysis to ensure
sensitive and reliable determination of small amounts of
product formed in a difficult matrix. One fully automatable
strategy is application of online solid-phase extraction
(SPE), which enables direct injection of crude samples
[23–25]. One of the most promising techniques for online
SPE of protein-containing samples is the application of
short, narrow columns filled with large particles (50–
60 μm) [23–25]. At high flow rates, turbulent flow results,
enhancing mass transfer between the mobile and stationary
phases. This enables the separation of the small analyte
molecules from the matrix, because of the larger diffusion
coefficient of proteins [23–25]. Turbulent-flow chromatog-
raphy (TFC) significantly reduces matrix effects by proteins
in LC–ESI–MS quantification[26], and has found broad
application in bioanalytical research, particularly for the
analysis of drugs in biological samples [23–25, 27]. TFC
was recently introduced as sample preparation for ESI–MS
based enzyme inhibition assays by Vogel and coworkers
[11]. In this work, we developed one of the fastest online
SPE–LC–ESI–MS–MS methods described, by combining
TFC with a separation on a sub-2 μm core–shell particle-
filled RP-18 separation column. Together with a stream-
lined sEH inhibition assay in plate format, this method
enables ranking of sEHIs with picomolar potencies by
utilizing the endogenous substrate 14(15)EpETrE.
Experimental
Chemicals and biological materials
14(15)-Epoxy-eicosatrienoic acid (14(15)-EpETrE) and
14,15-dihydroxyeicosatrienoic acid (14,15-DiHETrE)
(Fig. 1) were purchased from Cayman Chemicals (Ann
Arbor, MI, USA). The internal standards, 10(11)-epoxyde-
caheptanoic acid (10(11)-EpHep) and 10,11-dihydroxyde-
caheptanoic acid (10,11-DiHHep) were synthesized as
described elsewhere [18]. Urea derivatives previously
synthesized in our laboratory were used as epoxide
hydrolase inhibitors (sEHI) [28–32]. The chemical struc-
tures of four of the inhibitors are shown in Figs. 2 and 3.
All other chemicals were obtained from Fischer Scientific
(Pittsburgh, PA, USA) and were of the highest quality
available. Baculovirus-expressed human soluble epoxide
hydrolase (sEH) was purified by affinity column chroma-
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Fig. 1 SRM chromatogram obtained from the online SPE–LC–MS/
MS system. The signals of the product 14,15-DiHETrE (black line at
0.9 min) and its I.S. 10,11-DiHHep (red line at 1.0 min) and the co-
eluting substrate 14(15)-EpETrE (green) and its I.S. 10(11)-EpHHep
(dashed blue line) at 1.6 min are shown after injection of 20 μL
standard solution containing 100 nmol L
−1 of the compounds. The
relative intensity (y-axis) of each SRM transition is shown normalized
to 100% intensity. The structure of the analytes is depicted beside of
the peaks
1360 N.H. Schebb et al.tography and its 100 μmol L
−1 stock solutions in sodium
phosphatebuffer(100mmolL
−1 pH 7.4) was kept at −80 °C
until use [33].
Preparation of stock and standard solutions
Stock solutions of 14(15)-EpETrE, 14,15-DiHETrE, 10
(11)-EpHep, 10,11-DiHHep, and sEHIs were prepared in
DMSO and kept at 4 °C. All solutions for the assay were
prepared on the day of analysis in 0.1 mol L
−1 sodium
phosphate buffer (pH 7.4) containing 0.1 gL
−1 bovine
serum albumin (BSA) and kept on ice until incubation. For
the assay a 1 μmol L
−1 enzyme solution of sEH was
prepared from the stock solution in buffer; this was stable at
4 °C for seven days. Before the incubation, this solution
was further diluted with buffer to concentrations of 0.1,
0.33, and 1 nmol L
−1. The substrate solution was freshly
prepared by 1:100 dilution from the 1.5 mmol L
−1 DMSO
stock solution to 14,(15)-EpETrE in buffer (15 μmol L
−1,
1% DMSO).
Inhibitor solutions of 3, 10, 30, and 100 μmol L
−1
were prepared by diluting stock solutions in buffer (final
DMSO concentration: 1%) within an hour before analysis
and subsequently further diluted as described in the
section “sEH inhibition assay”. The reaction quench
solution consisted of 20 μmol L
−1 sEHI (1) and
200 nmol L
−1 of the I.S. 10(11)-EpHep and 10,11-
DiHHep in ACN–water 50:50 (v/v). For calibration a
0.5 mmol L
−1 DMSO solution of 14(15)-EpETrE and
14,15-EpETrE was sequentially diluted in a 96-well plate
in 50:50 (v/v)A C N –water. Subsequently, the dilutions
were mixed 1:1 with quench solution (final concentration
0.04 nmol L
−1–2.5 μmol L
−1) and analyzed in the same
way as samples.
Instrumental setup
Online SPE-LC was performed in back-flush mode utilizing
a setup similar to that recently described [27]. In brief, the
analytes (injection volume 20 μL) were extracted using a
(50×0.5 mm, 50 μm particle size) Cyclone RP-18 column
(Thermo Fisher Scientific, Waltham, MA, USA) at a flow
rate of 1500 μL min
−1 0.1% acetic acid. After 30 s the six-
port valve was switched, and the analytes were separated by
a 78-s binary gradient on a (50×2.1 mm) Kinetex core–
shell reversed-phase column (Phenomenex, Torrance, CA,
USA) at a flow rate of 500 μL min
−1. Mass spectrometric
detection was carried out in selected reaction monitoring
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Fig. 3 Typical IC50 curves of the inhibition of human sEH by three
different sEHI. Shown are the mean and deviation from duplicate
determination. The structures of the sEHI are depicted beside the
curves
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Fig. 2 Reproducibility and robustness of the method. Shown are the
dose–response curves for sEHI 1. a Means of three independent
determinations on three different days, using two different batches of
substrate and enzyme. b Comparison of a direct measurement after
incubation and after 7 days storage at −30 °C. The structure of the
inhibitor is shown in panel A
Development of an online SPE–LC–MS-based assay 1361spectrometer after negative electrospray ionization (ESI).
Details of the instruments used, the gradients applied, and
the mass spectrometric conditions are presented in the
Electronic Supplementary Material.
sEH inhibition assay
All sEH incubations were carried out in polypropylene 96-
well plates (Fisher Scientific) in a heated (30 °C) shaker.
For optimizing sEH concentration and incubation time, all
wells were filled with 50 μL buffer. Enzyme solutions of 1,
0.33, and 0.1 nmol L
−1 and buffer as control (50 μL) were
added to two rows for each concentration, by use of a
twelve-channel pipette. Following pre-incubation for 5 min
the conversion was started by adding 50 μL substrate
solution. After 0, 5, 10, 20, and 40 min, 150 μL of quench
solution was added to two rows at each time point. After
incubation the plate was kept at 4 °C until online LC–MS–
MS analysis.
For the sEHI potency assay, wells in columns 2–12
were filled with 50 μL buffer. Column 1 wells were
f i l l e dw i t h7 5μL inhibitor solution (2–3 wells for each
inhibitor). By use of an eight-channel pipette, 25 μL
from each cell in row 1 was transferred to the cells in
row 2 and mixed three times with the pipette. This
procedure was repeated for rows 2–12, and, finally,
25 μL from row 12 cells was removed and discarded. No
inhibitor was added to wells G12 and H12, which served
as positive and negative control, respectively. Thereafter,
50 μL enzyme solution was added to all wells (except
the negative control H12, to which 50 μL additional
buffer was added instead) and the plate was pre-
incubated for 5 min. After addition of 50 μLs u b s t r a t e
solution (0.1 μmol L
−1) to all wells with a twelve channel
pipette, the plate was incubated for 30 min. The reaction
was stopped by adding 150 μL quench solution to all
wells and directly analyzed by online LC–MS–MS, or
kept at 4 °C till analysis. The measured effect on sEH
activity for each well was calculated as percentage of sEH
inhibition based on the area ratio, R, of the product 14,15-
DiHETrE and its internal standard, 10,11-DiHHep by use
of Eq.(1).
inhibition % ðÞ ¼ 100  
Rsample   Rnegative control

  100
Rpossitive control   Rnegative control
ð1Þ
The IC50 for the sEHI were calculated by fitting the
dose–response curves of percentage inhibition values vs.
log concentration with Origin 7.0 (OriginLab, MA, USA).
The potency of the sEHI was compared with the value
from the commonly used fluorescence assay utilizing cyano
(6-methoxynaphthalen-2-yl)methyl trans-[(3-phenyloxiran-
2-yl)methyl] carbonate (CMNPC) as substrate as described
elsewhere [3, 4].
Results and discussion
Online SPE–LC–ESI–MS–MS
In the development of the new sEH inhibition assay a major
emphasis was set on a rapid method of detection of the
substrate 14(15)-EpETrE and its hydrolysis product 14,15-
DiHETrE (Fig. 1). The odd-chain fatty acid epoxide 10,
(11)-EpHep and its corresponding diol, 10,11-DiHHep
(Fig. 1) were used as internal standards. These were chosen
because they have similar physicochemical properties to the
arachidonate oxylipins, and they do not occur biologically
in relevant amounts. The crude samples arising from
enzymatic incubations were mixed with I.S. solution and
directly analyzed by online-SPE–LC–MS–MS (Electronic
Supplementary Material Fig. S1). The analytes were
completely extracted by the online-SPE column and no
analyte was detected in the flow through up to an elution
volume of 6 mL (Electronic Supplementary Material
Fig. S2). Salts and protein were directed to waste, and a
minimum extraction time of 30 s corresponding to elution
of 20 void volumes of the SPE column was found to be
sufficient. Thereafter, the six-port valve was switched and
the analytes were eluted in back-flush mode from the SPE
column by the more hydrophobic flow (57% ACN)
delivered by pump 2 (Electronic Supplementary Material
Fig. S1). The separation was carried out on a short 50×
2.1 mm, 1.7 μm not fully porous “core-shell” particle filled,
RP-18 column at a flow rate of 500 μL min
−1. Efficient
mass transfer between stationary and mobile phases results
from the short diffusion path in the shell type particles [34,
35]. In addition to the advantages of sub-2-μm particle size,
this column type leads to very high chromatographic
resolution [36]. The mobile phase gradient was optimized
to fully separate analytes from the void volume (150 μL) of
the analytical column where polar matrix compounds co-
extracted by SPE elute (Fig. 1). The dihydroxy fatty acid I.
S. 10,11 DiHHep eluted first at a retention time of 59±1 s
followed by 14,15-DiHETrE at 63±1 s. Despite the
proximity of the retention times, these compounds were
separated almost to the baseline, because of the narrow
peak width, with full width at half maximum height
(FWHM) of 1.4±0.1 s and 1.5±0.1 s, respectively
(Fig. 1). After elution of the diols, the gradient was
increased to 95% ACN over a period of 6 s to elute the
epoxides. The 14,(15)-EpETrE and its I.S. 10,(11)-EpHept
co-eluted at 96±1 s as narrow peaks (Fig. 1). Although it is
not ideal that the substrate and its I.S. co-elute, quantifica-
tion for the assay was carried out on the basis of product
1362 N.H. Schebb et al.formation, and the product and its I.S. are ideally baseline
separated. MS detection of the fatty acid derivatives was
carried out after negative ESI in selected reaction monitor-
ing mode (SRM), using the same transitions as previously
described [18, 19].
A disadvantage inherent in the application of online SPE
is the risk of carry over from the previous sample [25]. To
investigate carry over, the highest concentration sample
(2.5 μmol L
−1) was injected and the analyte area obtained
was compared with that for a subsequent blank injection.
We found carry-over was 0.1% for 14,15-DiHETrE and
0.4% for 14(15)-EpETrE. Therefore it is expected there will
be negligible interference from carry-over in the assay.
The method was calibrated using a series of standard
solutions of 14,15-DiHETrE and 14(15)-EpETrE, which
were treated in the same manner as incubation samples. The
limit of detection (LOD, S/N=3) for 14,15-DiHETrE and
14(15)-EpETrE was 0.1 nmol L
−1 (2 fmol on column) and
method provided for both analytes a broad linear detection
range over three orders of magnitude (R
2≥0.999) from the
limit of quantification (LOQ, S/N=9) up to 800 nmol L
−1.
To investigate matrix effects on the quantification, we
spiked the protein-containing reaction buffer with 10–
800 nmol L
−1 of the analytes. These concentration ranges
correspond to the product concentration at a conversion rate
of 0.2–30% of the enzymatic assay (section “sEH inhibition
assay”). As shown in Electronic Supplementary Material
Fig. S3, recovery of the analytes was within ±20% for all
the concentrations tested, so direct injection of quenched
incubation samples did not compromise analytical perfor-
mance. because of the ultra-rapid online-SPE–LC–MS–MS
(total analysis time 1.8 min) more than 30 samples can be
analyzed in one hour, rendering this approach ideal for
enzyme inhibition assays with a large sample sets.
sEH inhibition assay
The enzyme inhibition assay was developed in a robust 96-
well-plate format for rapid investigation of sEHI libraries.
In a final volume of 150 μL the assay was carried out by
mixing equal volumes (50 μL) of inhibitor (buffer for
controls), substrate, and enzyme solution followed by
incubation. All pipetting steps were performed with a
volume of at least 25 μL, enabling reproducible use of
multichannel pipettes and making adaptation for use with
fully-automated pipetting robots easily possible. The
enzyme assay was carried in 0.1 mol L
−1 sodium phosphate
buffer (pH 7.4) containing 0.1 gL
−1 bovine serum albumin
(BSA) at 30 °C, as described previously [3]. The substrate
concentration in the assay was set to the KM value of
5 μmol L
−1 for the conversion of 14(15)-EpETrE by human
sEH[37]. Incubation time and enzyme concentration were
optimized to keep the enzyme concentration as low as
possible to enable measurement of IC50 values for potent
inhibitors. It was found that an enzyme concentration of
only 33.3 pmol L
−1 was sufficient. The conversion of 14
(15)-EpETrE was linear over the incubation time. Within
30 min, 298±18 nmol L
−1 14,15-DiHETrE was formed.
This corresponds to substrate conversion of 5.9±0.4% and
thus indicates that the initial velocity of the enzyme
reaction was constant over the whole incubation time.
Because of the high sensitivity of the online LC–ESI–MS–
MS method, low product concentrations can be reliably
quantified (section “Online SPE–LC–ESI–MS–MS”). Be-
cause no significant non-enzymatic chemical hydrolysis of
the substrate occurred (0.13±0.06%), the approach enables
quantitative measurement of sEH inhibition with a good
signal-to-noise ratio based on product formation. However,
the substrate concentration in the samples exceeds the
dynamic range of the detection method, and thus could not
be monitored simultaneously, although it would be techni-
cally feasible to do so. After the incubation, the reaction
was stopped by adding an equal volume of quenching
solution (150 μL). The ACN content of this solution was
adjusted to be as high as possible to denature the enzyme
and increase the solubility of the low polar oxylipins.
However, concentrations above 50% ACN in water in the
quenching solution caused precipitation of proteins and
salts, making direct injection into the online SPE–LC–MS–
MS system impossible. When 50:50 (v/v) ACN–water was
used as the quenching solution, it was also found that sEH
was not fully inactivated by the organic solvent and the
14,15-DiHETrE concentration increased in the quenched
samples over time. Therefore sEHI (1) was added to the
quenching solvent at a high concentration of 20 μmol L
−1
to fully inactivate the enzyme. With this optimized
quenching solution incubation samples were stable over a
storage time of at least 7 days at −20 °C or 4 °C (Fig. 2).
Measurement of sEHI potency was carried out by
investigating 14,15-DiHETrE formation in the presence of
twelve concentrations of each inhibitor compared with
control samples. In a generic scheme, 50 μLo f3μmol L
−1
solutions of sEHI in buffer (1% DMSO) were added to the
wells of the first row of a 96-well plate and were
sequentially diluted threefold per step. The resulting series
of dilutions (final concentration in assay 6 pmol L
−1–
1 μmol L
−1) enabled the direct determination of sEHI
potency within a wide dynamic range. To ensure the
accuracy of the measurements, at least three concentrations
above and three concentrations below the IC50 should be
investigated [38]. The dilution series therefore enabled the
evaluation of sEHI with an IC50 range of 0.1 nmol L
−1 to
100 nmol L
−1, without any modification of this procedure.
However, for investigation of sEHI of low potency (high
IC50 value), the initial concentration of the inhibitor
solution was increased to 3.3, 10, and 33.3 μmol L
−1. The
Development of an online SPE–LC–MS-based assay 1363resulting dose–response curves for sEHI inhibitors had a
nearly theoretical sigmodial shape as shown in Fig. 3 for
three inhibitors of significantly different potency. Together
with the precise online SPE–LC–ESI–MS–MS measure-
ment (intra sample variation <5%) this yielded consistent
data sets for each inhibitor, which could be accurately fitted
to obtain IC50 values (Fig. 3). The precision and reproduc-
ibility of the approach was demonstrated by repeated
investigation of sEHI (1) (Fig. 2). The variation in the
IC50 values of three replicates on a single plate (intra-plate
variation) was consistently low (15±6%, n=9). The intra-
day variation of three independent investigations on three
different plates on a single day (n=3) was also good (9±
6%). The inter-day stability was calculated on the basis of
the potencies determined on three different days using
different batches of enzyme and substrate solution. The
IC50 values for sEHI (1) were 2.1±0.1, 1.9±0.1, and 3.1±
0.5 nmol L
−1. The resulting intraday variation of only 25%
emphasizes the robustness of the approach, rendering it
ideal for the determination of sEHI potency with high
precision.
Investigation of the potency of a library of sEHI
To demonstrate the performance of this approach a library
of 13 competitive inhibitors, sEHI 11–23, was investigated
for their potency, and the results obtained were compared
with those from the commonly used fluorescence assay
with CMNPC as surrogate substrate. As shown in Table 1
the IC50 of the investigated sEHI varied over three orders of
magnitude from 2 nmol L
−1 to 1300 nmol L
−1 based on the
fluorescence assay. It was found that IC50 values obtained
with the LC–MS based assay using the natural substrate
and the fluorescence assay correlated well, with a linear
correlation coefficient between the methods of R
2=0.9
(Fig. 4). Because the slope of the linear correlation (potency
fluorescence vs. natural substrate assay) was 0.95 overall
the same potencies were obtained by both methods.
Moreover, both methods sort the potency of tested sEHI
in the same rank order, with a Spearman’s rank correlation
coefficient of 0.9. When comparing individual sEHI, the
difference between both methods was generally lower than
a factor of 2 (Table 1, Fig. 4). The two exceptions to the
excellent correlation of IC50 values between the assays
were sEHI (14) and sEHI (21). The IC50 value obtained by
the new natural substrate assay was eightfold higher IC50
for sEHI (14) and a factor of 6 lower for sEHI (21) than
those obtained from the fluorescence assay. However, these
differences in IC50 values also occur between sEH assays
utilizing different surrogate substrates. Tsai et al. reported
recently reported strong variances between the potencies
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Fig. 4 Correlation of measured IC50 values between the newly
developed LC–MS approach and the high-throughput fluorescence
assay. The linear regression for inhibitors with IC50>1 nmol L
−1 in the
florescence assay is shown in grey. The LC–MS assay results for
potent inhibitors (fluorescence assay≤1 nmol L
−1) is shown enlarged
in the inset, demonstrating that the fluorescence assay cannot
distinguish among the most potent sEHI
Table 1 Determined IC50 values for inhibition of human sEH for a
small library of 23 different urea derivatives. The results from the
developed LC–MS assay are compared with those from the commonly
used fluorescence (FD) assay
Inhibitor
no.
IC50 FD assay
(nmol L
−1)
IC50 LC–MS assay
(nmol L
−1)
1 ≤1 2.4±0.6
2 ≤1 0.7±0.3
3 ≤1 5.4±0.9
4 ≤1 1.8±0.5
5 ≤1 4.9±1.3
6 ≤1 1.3±0.4
7 ≤1 1.3±0.3
8 ≤1 1.4±0.1
9 ≤1 5.0±0.1
10 ≤1 2.2±0.3
11 2 3.2±0.3
12 4 4.4±0.2
13 3 7.3±3.1
14 3 22.5±3.8
15 14 13.1±5.4
16 15 16±0.4
17 28 18.2±2.8
18 39 24±5
19 133 171±25
20 284 368±51
21 684 111±20
22 1011 567±81
23 1441 1323±26
1364 N.H. Schebb et al.observed by the fluorescence assay using CMNPC as
substrate and the radiometric assay utilizing t-DPPO as
substrate [32]. For example the IC50 value for sEH 16
(Fig. 3) was twentyfold higher for the radiometric assay
compared with the fluorescence assay. Interestingly, the
potency of this sEH determined with the natural substrate
assay was in general agreement with those from the
fluorescence assay (Table 1, Fig. 4). All tested sEHi were
urea derivatives, for which it is known that they only act as
competitive inhibitors [29–32]. Thus it is unlikely that an
allosteric or irreversible inhibitory mode of action of the
inhibitors causes the differences in the measured potencies.
On the basis of on these findings, it is concluded that the
IC50 value obtained for sEHI is not only affected by assay
conditions, but is also dependent on the substrate used. The
major mode of action of sEHI as a potential pharmaceutical
is thought to be the stabilization of biologically active fatty
acid epoxides, for example 14(15)-EpETrE [1, 39]. Thus,
the values obtained from the natural substrate assay
described in here should be more predictive of the efficacy
of the sEHI in vivo.
T h es E Hc o n c e n t r a t i o nu s e di nt h i sa s s a yi so n l y
33 pmol L
−1. This concentration is significantly lower than
that used in other methods (1 nmol L
−1)[ 3–6]. Given that
the lowest IC50 value which can be reliable determined with
an enzyme activity assay is equivalent to the enzyme
concentration, this method is capable of quantitatively
determining the potency of compounds with thirtyfold
higher potency than all other methods up to an IC50 value
as low as 0.03 nmol L
−1. For the first time, the potency of
the most powerful sEHI can be quantitatively investigated.
This unique feature of the new method was demonstrated
by ranking the competitive sEHI (1–10) by their potency.
All these inhibitors have potency≤1 nmol L
−1 in the
fluorescence assay (Fig. 4; Table 1). However, none of
these compounds had a potency significantly higher than
1 nmol L
−1 in the natural substrate assay. Moreover, many
of the potent sEHI had IC50 values of 5 nmol L
−1 and
higher, as predicted by the fluorescence method. With
potency of approximately 0.7±0.3 nmol L
−1, sEHI (2)
(Fig. 3) is the most potent of the inhibitors in the compound
library investigated. This is comparable with the potencies
of best sEHI inhibitors described so far [31]a n dn o
picomolar sEHIs were identified in this study. Nevertheless,
the new approach described herein would enable charac-
terization of picomolar IC50s, and thus might lead to the
development of still more potent sEHI.
Conclusion
An e w ,L C –MS-based natural substrate approach for
potency measurement of sEHI has been developed. In
combination with a generic assay scheme in 96-well plate
format, this new method enables reliable measurement of
the potency of sEHI with high precision. By application of
one of the fastest online SPE–LC–MS–MS systems
described, just less than 22 min were needed for determi-
nation of the potency of a single compound. With an
analysis time of 2.8 h per 96-well plate, this assay cannot
compete with spectral or fluorescence-based high-
throughput assays. However, investigation of a small sEHI
library indicates that, despite good overall correlation with
data from surrogate assays, the determined potency for
individual sEHI is substrate-dependent. The mode of action
of sEHI in vivo is thought to be the stabilization of fatty
acid epoxides. Thus, the utilization of an assay using the
endogenous substrates is indispensable for reliable struc-
ture–activity relationship (SAR) analysis of sEHIs. With the
method described herein, a fast highly automated technique
is now available, which enables further development of
highly potent sEHI.
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